GWM
CORT icon

Geneos Wealth Management’s Corcept Therapeutics CORT Stock Holding History

Geneos Wealth Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-77
Closed -$5.65K – 2634
2025
Q2 		$5.65K Sell
77
-11
-13% -$798 ﹤0.01% 2536
2025
Q1 		$10.1K Buy
88
+17
+24% +$1.03K ﹤0.01% 2247
2024
Q4 		$3.58K Hold
71
– – ﹤0.01% 2446
2024
Q3 		$3.29K Buy
+71
New +$2.52K ﹤0.01% 2182
2020
Q3 		– Sell
-1,000
Closed -$16K – 2640
2020
Q2 		$16K Buy
+1,000
New +$14K ﹤0.01% 1715
2017
Q2 		– Sell
-200
Closed -$2K – 2084
2017
Q1 		$2K Buy
+200
New +$1.76K ﹤0.01% 1865

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geneos Wealth Management's CORT Position: Q3 2025 in Review

Geneos Wealth Management sold out of Corcept Therapeutics (CORT) in Q3 2025, closing a stake of 77 shares — an estimated $5.65K sold.

Geneos Wealth Management first reported a position in CORT in Q1 2017 and held it in 6 quarters. The position peaked at $16K in Q2 2020. 429 funds tracked by Wall St. Rank hold CORT as of Q3 2025.

  • Geneos Wealth Management reported no remaining Corcept Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 77 Corcept Therapeutics shares in Q3 2025, an estimated $5.65K.
  • Geneos Wealth Management first reported a position in Corcept Therapeutics in Q1 2017 and held it in 6 quarters.
  • Geneos Wealth Management's Corcept Therapeutics position peaked at $16K in Q2 2020.
  • 429 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.